The earnings call highlighted significant revenue growth and strategic acquisitions, particularly the acquisition of Previse and the strong performance of TissueCypher. However, challenges were noted in gross margin decline, discontinuation of IDgenetix, and reimbursement issues for DecisionDx-SCC. Despite these challenges, the positive developments appear to outweigh the negatives.

Company Guidance -

Q1 2025

During the Castle Biosciences First Quarter 2025 Conference Call, the company reported a 21% revenue increase to $88 million, driven by a 33% rise in test report volume compared to the same period in 2024. The company highlighted a strong balance sheet with $275 million in cash, cash equivalents, and marketable investment securities. Castle Biosciences announced the acquisition of Previse to strengthen its position in the gastrointestinal space and reported that its DecisionDx-Melanoma test surpassed 200,000 orders. Additionally, DecisionDx-SCC delivered 4,375 test reports in Q1 2025 and TissueCypher saw a 117% growth in test reports year-over-year. The company also raised its total revenue guidance for 2025 to $287-$297 million. Adjusted gross margin was reported at 81.2%, and the company experienced a net loss of $25.8 million for the quarter.

Revenue Growth

Revenue grew by 21% to $88 million, and test report volume for core revenue drivers increased by 33% compared to the first quarter of 2024.

Strong Balance Sheet

The company has a strong balance sheet with $275 million in cash, cash equivalents, and marketable investment securities.

Previse Acquisition

Castle Biosciences signed a definitive agreement to acquire Previse, enhancing its position in the gastrointestinal space.

TissueCypher Growth

TissueCypher test reports grew by 117% year-over-year, delivering 7,432 test reports in the first quarter of 2025.

DecisionDx-Melanoma Milestone

DecisionDx-Melanoma surpassed 200,000 test orders since its launch.

Castle Biosciences (CSTL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CSTL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 11, 2025	2025 (Q2)	-0.51 / -	0.31	―	―	―
May 05, 2025	2025 (Q1)	-0.07 / -0.90	-0.09	-900.00% (-0.81)
Feb 27, 2025	2024 (Q4)	0.05 / 0.32	-0.1	420.00% (+0.42)
Nov 04, 2024	2024 (Q3)	>-0.01 / 0.08	-0.26	130.77% (+0.34)
Aug 05, 2024	2024 (Q2)	-0.27 / 0.31	-0.7	144.29% (+1.01)
May 02, 2024	2024 (Q1)	-0.33 / -0.09	-1.1	91.82% (+1.01)
Feb 28, 2024	2023 (Q4)	-0.56 / -0.10	-0.78	87.18% (+0.68)
Nov 02, 2023	2023 (Q3)	-0.76 / -0.26	-0.77	66.23% (+0.51)
Aug 02, 2023	2023 (Q2)	-0.92 / -0.70	-0.06	-1066.67% (-0.64)
May 03, 2023	2023 (Q1)	-0.89 / -1.10	-0.97	-13.40% (-0.13)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CSTL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 05, 2025	$18.75	$16.62	-11.36%
Feb 27, 2025	$25.28	$21.68	-14.24%
Nov 04, 2024	$33.64	$31.15	-7.40%
Aug 05, 2024	$21.85	$24.90	+13.96%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Castle Biosciences (CSTL) report earnings?

Castle Biosciences (CSTL) is schdueled to report earning on Aug 11, 2025, After Close (Confirmed).

What is Castle Biosciences (CSTL) earnings time?

Castle Biosciences (CSTL) earnings time is at Aug 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CSTL EPS forecast?

CSTL EPS forecast for the fiscal quarter 2025 (Q2) is -0.51.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing